of treatment with alprazolam in their four-drug, placebo-controlled cross-over trial. As noted earlier, this study included female borderline patients with comorbid hysteroid dysphoria and past histories of impul-sive behavior. On an average daily dosage of 4.7 mg alprazolam, seven of 12 (58%) patients taking alprazolam had serious episodes of behavior dyscontrol compared to one of 13 (8%) taking placebo. Episodes of behavior dyscontrol involved drug overdoses, wrist and neck cuts, and throwing a chair at a child. Four alprazolam trials were stopped by the blind rater for dyscontrol while none of the placebo trials were discontinued.

DOI link for of treatment with alprazolam in their four-drug, placebo-controlled cross-over trial. As noted earlier, this study included female borderline patients with comorbid hysteroid dysphoria and past histories of impul-sive behavior. On an average daily dosage of 4.7 mg alprazolam, seven of 12 (58%) patients taking alprazolam had serious episodes of behavior dyscontrol compared to one of 13 (8%) taking placebo. Episodes of behavior dyscontrol involved drug overdoses, wrist and neck cuts, and throwing a chair at a child. Four alprazolam trials were stopped by the blind rater for dyscontrol while none of the placebo trials were discontinued.

of treatment with alprazolam in their four-drug, placebo-controlled cross-over trial. As noted earlier, this study included female borderline patients with comorbid hysteroid dysphoria and past histories of impul-sive behavior. On an average daily dosage of 4.7 mg alprazolam, seven of 12 (58%) patients taking alprazolam had serious episodes of behavior dyscontrol compared to one of 13 (8%) taking placebo. Episodes of behavior dyscontrol involved drug overdoses, wrist and neck cuts, and throwing a chair at a child. Four alprazolam trials were stopped by the blind rater for dyscontrol while none of the placebo trials were discontinued.